Join
Live feed
·
PRReleasevia Quantisnow
Relay Therapeutics Inc. logo

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

ByQuantisnow·Wall Street's wire, on your screen.
RLAY· Relay Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLAY (Relay Therapeutics Inc.) and more on Quantisnow.